Unsorted prescription pills sit in a pharmacist's counting tray before they are bottled.

UK, UNC research will help FDA make opioid regulatory decisions

Opioid Abuse Treatment, Opioids, Opioid Addiction

The United States Federal Drug Administration has given a four-year $3.3 million contract to researchers at UK and the University of North Carolina at Chapel Hill to conduct studies that will provide the agency with information vital to making regulatory decisions regarding opioids.

Svetla Slavova, PhD, associate professor of biostatistics in the UK College of Public Health's Kentucky Injury Prevention and Research Center, will lead work that includes collaboration with the Kentucky All Schedule Prescription Electronic Reporting (KASPER) system, the Kentucky Office of Vital Statistics and the Office of the Chief Medical Examiner. Her team will continue to develop electronic linkage and connectivity of prescribing, mortality and toxicology data in Kentucky.

"The data will then be used to provide the FDA with improved monitoring of emerging medication risks," Slavova said. “The timeliness of data availability could revolutionize our concept of what can be learned about newly marketed drugs.”

"A panoramic portrait of the opioid crisis" 

Faculty at UK and UNC will also conduct research to help the FDA better understand the use of opioid therapies and products designed to prevent abuse – and the impact of the products on use, overdose and fatalities.

The research studies will increase the FDA’s knowledge of data systems and methods used in studying the impact of new medications as well as develop new data resources and methods that will be available as open-source research tools.

“We will develop a panoramic portrait of the opioid crisis, rather than a series of isolated data snapshots,” said Nabarun Dasgupta, PhD, senior research scientist at the UNC Injury Prevention Research Center and lead investigator on the project. “We’ll fundamentally improve the quality of information available to the FDA for regulatory decisions regarding opioids.”

The FDA may also add additional studies to extend the scope of the research in the second year of the project. These studies would engage scientists from RTI International and IBM Watson Health to further explore the themes of epidemiologic theory and methods and the lived experience of patients.

Uniting a multidisciplinary team

“The project unites UK and UNC – both powerhouses of research and practice in the areas of injury prevention and opioid addiction – in our common goal of turning the tide of the opioid crisis,” said Donna K. Arnett, PhD, dean of the UK College of Public Health. “The work undertaken by this impressive group of researchers will develop new tools to support FDA decision-making on opioid deterrence, with the potential to greatly improve population health nationwide.”

The multidisciplinary project team includes pain management physicians, pharmacists, ethnographers, people who use drugs, people living with chronic pain, statisticians, epidemiologists, state government officials and policy makers.

Other partnering institutions include DePaul University, Sawbuck Productions, Urban Survivors Union, the UK College of Pharmacy’s Institute for Pharmaceutical Outcomes and Policy, and the University of Louisville.

Stay informed of the latest health stories by email.

This content was produced by UK HealthCare Brand Strategy.